Does Medicaid Cover Weight Loss Shots? A 2026 State-by-State Guide

Key Takeaways

• KFF counted 13 state Medicaid fee-for-service programs covering GLP-1s for obesity as of January 2026, after California, New Hampshire, Pennsylvania and South Carolina ended coverage on January 1, 2026; Massachusetts (MassHealth) ended coverage on July 1, 2026. Check your own state's preferred drug list before assuming either way.
• Most other states cover GLP-1s only for type 2 diabetes (Ozempic, Mounjaro) or for sleep apnea (Zepbound, after the December 2024 FDA approval).
• Prior authorization is required in nearly every state, with criteria including BMI thresholds, documented weight-loss attempts, and provider supervision.
• Federal law allows but does not require state Medicaid programs to cover obesity medications, leaving the decision to each state.
• If your state Medicaid doesn't cover weight loss shots, options include Wegovy/Zepbound savings cards (require commercial insurance), patient assistance programs, or compounded semaglutide/tirzepatide.

The short answer

Some Medicaid programs cover weight loss shots, but most don't. KFF counted 13 fee-for-service programs covering Wegovy or Zepbound for chronic weight management as of January 2026, and the list has kept shrinking: California, New Hampshire, Pennsylvania and South Carolina ended coverage on January 1, 2026, and Massachusetts followed on July 1, 2026. North Carolina reinstated coverage on December 12, 2025, Tennessee and New Mexico cover with prior authorization, and Michigan and Virginia cover only at very high BMI. Most states cover GLP-1s only for type 2 diabetes or sleep apnea, not weight loss.

Table of contents

1. The 30-second answer
2. The federal Medicaid framework for obesity drugs
3. States that cover weight loss shots through Medicaid (April 2026)
4. States that don't cover weight loss shots
5. What Medicaid does cover for GLP-1s in non-covering states
6. Prior authorization criteria across Medicaid plans
7. What to do if your state doesn't cover weight loss shots
8. Patient assistance programs and self-pay options
9. Compounded GLP-1s through state-licensed pharmacies
10. What changed on January 1, 2026
11. State status table, September 2026
12. The BALANCE model
13. Indications still covered after a state drops weight loss
14. Self-pay fallbacks for Medicaid enrollees
15. Per-state answers
16. FAQ
17. Sources
18. Footer disclaimers

The federal Medicaid framework for obesity drugs

Medicaid is jointly funded by federal and state governments. Each state runs its own Medicaid program within federal rules. For prescription drugs, federal law lets states decide whether to cover certain categories, including weight loss medications.

The relevant federal language: under the Social Security Act (Section 1927(d)(2)), states "may exclude or otherwise restrict" coverage of agents used for "anorexia, weight loss, or weight gain." This permissive exclusion has been the legal basis for many states excluding GLP-1 weight loss drugs from Medicaid formularies.

In November 2024, CMS proposed a rule that would have required Medicaid (and Medicare) to cover anti-obesity medications, treating obesity as a chronic disease. In early April 2025 the Trump administration said it would not finalize it (KFF Health News, May 21, 2025). The federal programs that actually exist in 2026 are voluntary: the BALANCE model for Medicaid, which states could apply to through July 31, 2026 and which runs through December 2031, and the Medicare GLP-1 Bridge, which runs from July 1, 2026 to December 31, 2027. Coverage remains state by state.

Three things matter for patients:

Thing 1: Federal law allows weight loss drug coverage but doesn't require it. States have full discretion.

Thing 2: Even non-covering states cover GLP-1s for diabetes and OSA. The exclusion is for "weight loss" indication, not for the medication itself.

Thing 3: State policies are evolving. A state that doesn't cover weight loss shots in 2026 may add coverage in 2027, and vice versa.

States that cover weight loss shots through Medicaid (April 2026)

The states with confirmed Medicaid coverage for at least one GLP-1 (Wegovy, Zepbound, or both) for chronic weight management:

State	GLP-1s covered for weight loss	Notable conditions
California	None for weight loss since January 1, 2026	Medi-Cal Rx removed Wegovy, Zepbound and Saxenda for weight loss; Wegovy still considered for MASH and cardiovascular indications, Zepbound for sleep apnea; under-21 requests reviewed under EPSDT
Connecticut	Wegovy	BMI 30+ or 27+ with comorbidity, PA required
Delaware	Wegovy, Zepbound	BMI 30+, lifestyle counseling documentation
Kansas	Wegovy	BMI 30+ or 27+ with comorbidity, PA required
Massachusetts	None for weight loss since July 1, 2026	MassHealth ended obesity coverage on July 1, 2026; diabetes and other approved indications continue
Michigan	Saxenda, Wegovy, Zepbound (restricted)	Since January 1, 2026: BMI 40 or higher, documented failure of phentermine and Qsymia, prescriber attestation that the drug is needed to avert bariatric surgery, 6-month authorizations (MDHHS bulletin L 25-73)
Minnesota	Wegovy	BMI 30+, PA required
New Hampshire	None for weight loss since January 1, 2026	NH DHHS notice of October 9, 2025 ended coverage of Saxenda, Wegovy and Zepbound prescribed solely for weight loss; coverage continues for type 2 diabetes, cardiovascular risk, severe sleep apnea and MASH
Pennsylvania	None for adults 21 and over since January 1, 2026	Under-21 coverage continues under EPSDT; coverage continues for type 2 diabetes, sleep apnea with obesity, cardiovascular risk reduction and MASH (Pennsylvania Health Law Project, December 22, 2025)
Rhode Island	Wegovy	BMI 30+, PA required
Vermont	Wegovy	BMI 30+, PA required
Virginia	Wegovy, Zepbound (restricted)	Since July 1, 2024: BMI over 40, or over 37 with comorbidities (Milliman, March 19, 2026)
Wisconsin	Wegovy	BMI 30+ or 27+ with comorbidity, PA

Coverage in these states is typically restricted to FDA-approved chronic weight management medications: Wegovy (semaglutide) and Zepbound (tirzepatide). Saxenda (liraglutide) is also covered in some states. Ozempic and Mounjaro are not covered for weight loss because their FDA-approved indications are different (type 2 diabetes for Ozempic and Mounjaro).

Even in covering states, formularies and PA criteria can change with each plan year. The rows above were checked against state notices and KFF as of September 5, 2026 where a source existed; rows for Connecticut, Delaware, Kansas, Minnesota, Rhode Island, Vermont and Wisconsin carry over from an earlier version of this table and have not been re-verified, so treat them as leads, not confirmation. States with verified coverage that the older table omitted are North Carolina (reinstated December 12, 2025), Tennessee (Wegovy and Zepbound preferred on the September 1, 2026 PDL) and New Mexico (BMI over 40, or over 35 with hypertension, diabetes or dyslipidemia). Always verify directly with your state Medicaid agency or managed care plan.

States that don't cover weight loss shots

Most state Medicaid programs do not cover GLP-1s for chronic weight management. KFF's January 2026 count left 13 covering fee-for-service programs, so roughly three quarters of states either never covered the obesity indication or have dropped it, and the number has moved several times since October 2025. That is why this page now lists dated status changes rather than a fixed count. Every state still covers GLP-1s for their diabetes indications, and KFF notes that Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea are covered as non-obesity indications even where weight-loss coverage has ended.

Some non-covering states have publicly indicated they're reviewing coverage decisions, particularly in light of the strong clinical evidence from SURMOUNT-1 (Jastreboff et al., NEJM 2022) and STEP 1 (Wilding et al., NEJM 2021). The financial impact is the central concern. The only public Medicaid net price is the $245 per 30-day supply that Novo Nordisk and Lilly agreed to for Wegovy and Zepbound under the federal BALANCE model (KFF, May 11, 2026; Milliman, March 19, 2026), and large states could see hundreds of thousands of eligible enrollees if coverage opens.

Coverage decisions are typically announced before each calendar year. If your state announces new coverage starting January 1, 2027, the change would apply to existing Medicaid enrollees automatically.

What Medicaid does cover for GLP-1s in non-covering states

Even if your state doesn't cover weight loss shots, Medicaid likely covers GLP-1s for two other conditions:

Type 2 diabetes. All state Medicaid programs cover at least one GLP-1 for type 2 diabetes management. Coverage typically includes Ozempic (semaglutide) and Mounjaro (tirzepatide), with prior authorization. If you have type 2 diabetes plus obesity, the GLP-1 prescription would be for diabetes management, and the weight loss is a side effect.

Obstructive sleep apnea. After the FDA approved Zepbound for moderate-to-severe OSA in adults with obesity in December 2024, many state Medicaid programs added coverage for this indication. Coverage criteria typically include BMI 30+, AHI 15+, and concurrent or attempted PAP therapy.

If you have either condition, coverage paths exist that don't require your state to cover "weight loss." Talk to your provider about whether you qualify based on a co-existing diagnosis.

Prior authorization criteria across Medicaid plans

PA criteria vary by state, but the most common requirements:

Criterion 1: BMI threshold. Either BMI 30+ alone, or BMI 27+ with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, OSA, or cardiovascular disease).

Criterion 2: Documented weight loss attempts. Most plans want a 6 to 12 month history of unsuccessful diet and exercise efforts. Some require formal participation in a structured weight loss program.

Criterion 3: Behavioral or lifestyle counseling. Ongoing engagement with diet, exercise, or behavioral therapy. Some states require referral to a registered dietitian or formal Medical Therapy Management (MTM) program.

Criterion 4: Step therapy. A trial of cheaper alternatives first. Some states require trying generic phentermine or naltrexone-bupropion before approving GLP-1s.

Criterion 5: Provider type. Some states require the prescription come from a primary care provider or endocrinologist. Direct-to-patient telehealth platforms may not qualify in some states.

Criterion 6: Medication-specific requirements. PA for Wegovy may differ from PA for Zepbound within the same state. Plans often prefer one over the other based on rebate negotiations.

Medicaid programs do not publish first-submission approval rates for these drugs, so treat any percentage you read as a vendor estimate. Denials often relate to incomplete documentation, which is fixable with a resubmission.

What to do if your state doesn't cover weight loss shots

Five paths to consider:

Path 1: Coverage through a different indication. If you have type 2 diabetes, Ozempic or Mounjaro is likely covered. If you have moderate-to-severe OSA, Zepbound is likely covered. Talk to your provider about whether you qualify.

Path 2: Patient assistance programs. Both Novo Nordisk (NovoCare) and Eli Lilly run patient assistance programs that provide free or low-cost medication for income-eligible patients without coverage. Income limits typically run up to 400% of the federal poverty level.

Path 3: Manufacturer self-pay programs. As of September 5, 2026, LillyDirect sells the Zepbound vial or KwikPen for self-pay at $299 (2.5 mg), $399 (5 mg) or $449 (7.5 to 15 mg) a month when you refill within 45 days, with free delivery or pickup at Walmart pharmacies. Novo Nordisk's self-pay Wegovy pen is $199 a month for a new patient's first two fills and $349 after that, and the Wegovy pill is $149 to $299 a month by dose. Medicaid enrollment does not block self-pay purchases.

Path 4: Compounded GLP-1s through state-licensed pharmacies. Compounded semaglutide had a month-1 median price of $197 and compounded tirzepatide $299 across 14 telehealth providers each on September 3, 2026, per the Compounded GLP-1 Price Index; no insurance is involved.

Path 5: Lobby for coverage. State Medicaid policies can change. Patient advocacy through your state representatives, state Medicaid agency public comment periods, or organizations like the Obesity Action Coalition can influence policy.

Patient assistance programs and self-pay options

Novo Nordisk Patient Assistance Program (NovoCare PAP):

• Eligibility: household income at or below 400% FPL, U.S. resident, no prescription drug coverage that covers Wegovy.
• What it provides: free Wegovy for up to 12 months, renewable.
• Application: NovoCare website, provider signs medical necessity portion.

Lilly Cares Patient Assistance Program:

• Eligibility: household income criteria (varies), U.S. resident, lack of insurance coverage for Zepbound.
• What it provides: free medication for eligible patients on the products Lilly currently lists in the program; check the live Lilly Cares product list for Zepbound before applying, because the list changes and we could not confirm it for this update.
• Application: Lilly Cares Foundation.

LillyDirect (self-pay vials):

• Eligibility: active prescription, U.S. resident, willing to pay self-pay.
• Pricing (September 5, 2026): $299 (2.5 mg), $399 (5 mg) or $449 (7.5 to 15 mg) a month for the vial or KwikPen when refilled within 45 days; $499 or $699 without the refill discount.

Manufacturer savings cards:

• Wegovy: requires commercial insurance, not Medicaid-eligible.
• Zepbound: requires commercial insurance, not Medicaid-eligible.

The savings cards (which advertise $25/month pricing) don't apply to any government coverage including Medicaid. Federal anti-kickback rules prohibit drug manufacturers from offering copay assistance to patients on government healthcare programs.

Compounded GLP-1s through state-licensed pharmacies

Compounded semaglutide and tirzepatide are prepared by state-licensed 503A or 503B compounding pharmacies in response to individual prescriptions. They contain the same active ingredients as Wegovy/Ozempic and Zepbound/Mounjaro, but they are not FDA-approved and are not interchangeable with brand-name products.

Pricing (Compounded GLP-1 Price Index, September 3, 2026):

• Compounded semaglutide: month-1 median $197 across 14 telehealth providers, range $88 to $299; month-4 median $224.
• Compounded tirzepatide: month-1 median $299 across 14 providers, range $149 to $470; month-4 median $299.
• Live figures and the provider list are in the Compounded GLP-1 Price Index.

When compounded makes sense:

• Your state Medicaid doesn't cover weight loss shots.
• You don't qualify for patient assistance programs.
• You want predictable monthly pricing without insurance paperwork.
• Brand-name self-pay prices are out of reach.

When brand-name medications make more sense:

• Your state Medicaid does cover Wegovy or Zepbound.
• You qualify for the manufacturer patient assistance program (free).
• You strongly prefer FDA-approved medications and can afford the cash or LillyDirect price.

A licensed clinician should help you weigh the trade-offs. Compounded medications have not undergone FDA review and are not interchangeable with brand-name products. Internal link: see why is my compounded semaglutide red for color guidance.

What changed on January 1, 2026: four states ended coverage, one came back

The coverage map moved more in the nine months after October 2025 than in the previous three years. KFF's budget survey counted 16 covering states in October 2025; by its January 16, 2026 update the count was 13. These are the changes we could tie to a state notice as of September 5, 2026.

State	Change	Effective	What Medicaid still covers	Source
California (Medi-Cal Rx)	Wegovy, Zepbound and Saxenda removed for weight loss	January 1, 2026	Wegovy for MASH and cardiovascular indications, Zepbound for sleep apnea, under-21 review under EPSDT	Medi-Cal Rx member notice
New Hampshire	Saxenda, Wegovy, Zepbound no longer covered when prescribed solely for weight loss	January 1, 2026 (notice dated October 9, 2025)	Type 2 diabetes, cardiovascular events, severe sleep apnea, MASH	NH DHHS provider notice
Pennsylvania	GLP-1s for weight loss ended for adults 21 and over	January 1, 2026	Under-21 via EPSDT; diabetes, sleep apnea with obesity, cardiovascular risk, MASH	Pennsylvania Health Law Project, December 22, 2025
South Carolina	Obesity coverage that began in late 2024 (about 1,300 beneficiaries, about $10 million a year) ended	January 1, 2026	Diabetes and other approved indications	KFF, January 16, 2026; KFF Health News, May 21, 2025
North Carolina	Removed Wegovy, Zepbound and Saxenda for obesity on October 1, 2025, then reinstated them	Reinstated December 12, 2025	Wegovy preferred; Zepbound and Saxenda require a documented Wegovy trial or reason it is unsuitable; phentermine, diethylpropion and phendimetrazine covered without prior authorization	NC Medicaid, December 19, 2025
Michigan	Coverage narrowed to BMI 40 and above with documented failure of phentermine and Qsymia and an attestation that the drug is needed to avert bariatric surgery; 6-month authorizations	January 1, 2026	All diabetes indications	MDHHS bulletin L 25-73 via Priority Health, December 15, 2025
Massachusetts (MassHealth)	Obesity coverage ended	July 1, 2026	Diabetes and other approved indications	State notice; see also KFF tracking

Two states moved the other way. Tennessee's TennCare added the class (public sources give start dates of August 1, 2025 and January 1, 2026) and its preferred drug list effective September 1, 2026 lists Wegovy and the Zepbound single-dose pen as preferred with prior authorization and quantity limits, with liraglutide and Saxenda non-preferred. Utah started a one-year pilot on July 1, 2025 (Milliman). Missouri added coverage in 2024.

State status table, September 2026: covering, restricted, ended, never covered

This is the honest version of a state-by-state table: only rows we could tie to a primary or near-primary source as of September 5, 2026 are marked, and everything else says so.

Status	States	Key condition
Covering with prior authorization	North Carolina, Tennessee, New Mexico, Missouri, Utah (pilot)	NC: Wegovy preferred, Zepbound and Saxenda step-through. TN: Wegovy and Zepbound preferred (September 1, 2026 PDL). NM: BMI over 40, or over 35 with hypertension, diabetes or dyslipidemia; 3-month initial authorization on MAD Form 635. UT: one-year pilot from July 1, 2025.
Restricted to very high BMI	Michigan, Virginia	MI: BMI 40 and above plus phentermine and Qsymia failure (January 1, 2026). VA: BMI over 40, or over 37 with comorbidities (July 1, 2024).
Ended	California, New Hampshire, Pennsylvania, South Carolina (January 1, 2026); Massachusetts (July 1, 2026)	Diabetes, cardiovascular, sleep apnea and MASH indications continue; PA and CA review under-21 requests under EPSDT.
Listed in older versions of this page, not re-verified	Connecticut, Delaware, Kansas, Minnesota, Rhode Island, Vermont, Wisconsin	Check the state PDL; KFF's 13-state January 2026 count is the best public tally.
Everything else	Remaining states	Assume no weight-loss coverage until the state PDL says otherwise; diabetes GLP-1s are covered everywhere.

The BALANCE model: a $245 net price your state can opt into

BALANCE is the federal replacement for the withdrawn 2024 proposed rule, and it is voluntary. Per KFF's May 11, 2026 explainer, the Medicaid track started May 1, 2026 (with a rolling start to January 1, 2027) and runs through December 2031; states had to apply by July 31, 2026. Covered products are all formulations of Foundayo, Mounjaro, Ozempic, Rybelsus, Wegovy and the Zepbound KwikPen. Milliman reports that Wegovy and Zepbound, all doses and indications, are available to participating state Medicaid programs at $245 per month, and KFF describes the same $245 per 30-day net price agreed by the manufacturers.

Track	Dates	Who pays what	Status as of September 5, 2026
Medicaid (BALANCE)	May 1, 2026 to December 2031; applications closed July 31, 2026	State pays about $245 per 30-day supply net; enrollee copay set by the state	Voluntary; ask your state Medicaid agency whether it applied
Medicare GLP-1 Bridge	July 1, 2026 to December 31, 2027	$50 a month copay for Wegovy pen and pill, Zepbound KwikPen and Foundayo; prior authorization; spending sits outside the $2,100 Part D cap	Live
Medicare Part D BALANCE track	Planned for January 2027	Would have added GLP-1s to Part D formularies	Indefinitely delayed as of April 21, 2026 (KFF)

For a Medicaid enrollee, BALANCE does not change what you pay at the counter; it changes whether your state can afford to say yes. If your state dropped coverage in January 2026 on cost grounds, BALANCE participation is the thing to ask your legislator about.

If your state dropped weight-loss coverage: the indications Medicaid must still cover

Every state notice we read carved out the same list, because these are approved indications outside the weight-loss exclusion in Section 1927(d)(2).

• Type 2 diabetes: Ozempic, Mounjaro and other GLP-1s approved for diabetes are covered in every state, usually with prior authorization.
• Cardiovascular risk reduction: Wegovy's indication for reducing major cardiovascular events in adults with established cardiovascular disease and overweight or obesity (approved March 2024) is covered as a non-obesity indication; KFF lists it among mandatory coverage, and the New Hampshire and Pennsylvania notices name it explicitly.
• MASH (fatty liver disease): Wegovy's MASH indication (August 2025) is named in the Pennsylvania, New Hampshire and Medi-Cal notices as still coverable.
• Obstructive sleep apnea: Zepbound for moderate to severe OSA in adults with obesity (December 2024) is named in the California, New Hampshire and Pennsylvania notices.
• Under 21: Pennsylvania and California route requests for children and young adults through EPSDT medical-necessity review, which sits outside the adult exclusion.

The practical move: ask your prescriber whether one of these diagnoses is documented in your chart. The New Hampshire notice puts it plainly: coverage ended for GLP-1s prescribed solely for weight loss.

Self-pay fallbacks for Medicaid enrollees (savings cards are excluded)

GoodRx's Medicaid page states it directly: Medicaid enrollees do not qualify for manufacturer savings cards. What Medicaid enrollees can use are the manufacturers' self-pay programs and cash prices, which fell sharply in 2025 and 2026. Prices below were seen September 5, 2026.

Option	Price	Terms
Wegovy pen, self-pay (NovoCare or TrumpRx)	$199 a month for a new patient's first two fills, then $349	Through December 31, 2026 for the introductory price; Wegovy HD 7.2 mg $399
Wegovy pill, self-pay	$149 (1.5 mg), $199 (4 mg), $299 (higher strengths)	Prescription required
Zepbound vial or KwikPen, LillyDirect	$299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg)	Refill within 45 days or the price rises to $499 or $699; free delivery or Walmart pickup
Foundayo (orforglipron) pill, LillyDirect	$149 (0.8 and 2.5 mg), $199 (5.5 mg), $299 (9 to 17.2 mg)	Approved April 1, 2026; 45-day refill rule
Ozempic pen, TrumpRx	$199 a month	Listed against a $1,028 original price
Compounded semaglutide	Month-1 median $197 (range $88 to $299), month-4 median $224	14 telehealth providers, September 3, 2026, the Compounded GLP-1 Price Index
Compounded tirzepatide	Month-1 median $299 (range $149 to $470), month-4 median $299	Same index and date; not FDA approved

Two cautions. Self-pay purchases do not count toward any Medicaid cost sharing, and a Medicaid enrollee who buys Wegovy at $199 is paying for a drug the program may cover for a different diagnosis, so ask about the indications above first.

Per-state answers: Pennsylvania, Michigan, North Carolina, Virginia, Texas and Louisiana

These are the state versions of the question people type most often. Each answer is dated September 5, 2026 and tied to the source named.

• Pennsylvania: No for adults 21 and over since January 1, 2026. Medical Assistance still covers GLP-1s for type 2 diabetes, sleep apnea with obesity, cardiovascular risk reduction and MASH, and anyone under 21 can still be approved through EPSDT (Pennsylvania Health Law Project, December 22, 2025).
• Michigan: Only at BMI 40 or higher, after documented failure of phentermine and Qsymia, with a prescriber attestation that the drug is needed to avert bariatric surgery, in 6-month authorizations (MDHHS bulletin L 25-73, effective January 1, 2026).
• North Carolina: Yes, with prior authorization, since December 12, 2025. Wegovy is preferred; Zepbound and Saxenda require a documented Wegovy trial or a reason it is unsuitable (NC Medicaid, December 19, 2025).
• Virginia: Only at BMI over 40, or over 37 with comorbidities, a restriction in place since July 1, 2024 (Milliman, March 19, 2026).
• Texas and Louisiana: We could not locate a current state notice confirming weight-loss coverage in either program as of September 5, 2026, and neither appears in KFF's January 2026 covering list; assume no coverage for the obesity indication and check the state preferred drug list. Both cover GLP-1s for type 2 diabetes.
• Tennessee: Yes, with prior authorization and quantity limits; Wegovy and the Zepbound pen are preferred on the September 1, 2026 TennCare PDL.
• New Mexico: Yes, with prior authorization at BMI over 40, or over 35 with hypertension, diabetes or dyslipidemia; 3-month initial authorization (New Mexico Health Care Authority).

FAQ

Does Medicaid cover Wegovy for weight loss?

As of September 5, 2026, a shrinking minority of states do. KFF counted 13 fee-for-service programs in January 2026; California, New Hampshire, Pennsylvania and South Carolina ended coverage on January 1, 2026 and Massachusetts on July 1, 2026, while North Carolina reinstated Wegovy as its preferred agent on December 12, 2025 and Tennessee lists Wegovy and Zepbound as preferred on its September 1, 2026 drug list. Most other states don't cover Wegovy for weight loss. All state Medicaid programs cover at least one GLP-1 for type 2 diabetes.

Does Medicaid cover Zepbound for weight loss?

As of September 2026 the verified Zepbound-for-weight-loss programs are fewer: Tennessee lists Zepbound as preferred (September 1, 2026 PDL), North Carolina covers it as non-preferred behind Wegovy, New Mexico covers it with prior authorization at BMI over 40 (or over 35 with a comorbidity), and Michigan and Virginia only at BMI 40 and above. California, Pennsylvania and Massachusetts no longer cover it for weight loss. After the December 2024 FDA approval for OSA, most states added Zepbound coverage for the OSA indication, regardless of weight management coverage status.

Does Medicaid cover Ozempic for weight loss?

No. Ozempic is FDA-approved for type 2 diabetes, not weight loss. Medicaid covers Ozempic only for the diabetes indication. Patients using Ozempic off-label for weight loss are not covered by Medicaid in any state.

Does Medicaid cover Mounjaro for weight loss?

No. Mounjaro is FDA-approved for type 2 diabetes. Medicaid covers Mounjaro only for the diabetes indication. The same medication (tirzepatide) for weight loss is sold as Zepbound, which has its own coverage rules.

Why don't most state Medicaid programs cover weight loss shots?

Federal law allows but doesn't require Medicaid coverage of weight loss medications. States cite cost as the primary reason for non-coverage. A 2024 CMS proposed rule would have required Medicaid coverage of anti-obesity medications, but the proposal was paused in early 2025.

What if I have type 2 diabetes and obesity?

Medicaid covers GLP-1s for diabetes management in every state. If you have type 2 diabetes, your provider can prescribe Ozempic or Mounjaro for diabetes management, and the weight loss is a side effect of the medication.

What if I have sleep apnea and obesity?

Following the December 2024 FDA approval of Zepbound for moderate-to-severe OSA, many state Medicaid programs cover Zepbound for OSA. Coverage requires BMI 30+, AHI 15+, and concurrent or attempted PAP therapy.

Can I use the Wegovy or Zepbound savings card with Medicaid?

No. Federal anti-kickback rules prohibit drug manufacturers from offering copay assistance to Medicaid, Medicare, TRICARE, or VA patients. The savings cards work only for patients with commercial insurance.

How do I check my state's Medicaid coverage for weight loss shots?

Visit your state Medicaid agency's website and search the preferred drug list (PDL) for "Wegovy" or "Zepbound." You can also call your managed care plan's member services line, or ask your provider's office to verify coverage.

What's the cheapest path to weight loss medication if Medicaid won't cover it?

For income-eligible patients, the manufacturer patient assistance programs (NovoCare PAP for Wegovy, Lilly Cares for Zepbound) provide free medication. For others, self-pay brand prices are now close to compounded prices: the Wegovy pill is $149 a month, the Wegovy pen $199 for the first two fills, and Zepbound $299 to $449 through LillyDirect, while compounded semaglutide and tirzepatide had month-1 medians of $197 and $299 on September 3, 2026.

Will Medicaid cover weight loss shots in my state someday?

Possibly. State Medicaid policies are evolving. KFF's count fell from 16 states in October 2025 to 13 in January 2026, and Massachusetts left in July 2026, so the 2026 trend is toward less coverage; the BALANCE model's $245 net price is the main reason a state might reverse course. Federal CMS guidance, drug pricing negotiations, and state budget considerations all influence the trajectory.

Is compounded semaglutide or tirzepatide safe?

Compounded GLP-1s prepared by state-licensed 503A or 503B pharmacies under individual prescriptions follow USP standards for sterile compounding. They are not FDA-approved and have not undergone the same review as brand-name products. Patients should obtain compounded medications only from licensed pharmacies through licensed providers.

Does Medicaid cover weight loss shots in Pennsylvania?

Not for adults. Effective January 1, 2026, Pennsylvania Medicaid stopped covering GLP-1 medications prescribed for weight loss for anyone 21 and over, per the Pennsylvania Health Law Project (December 22, 2025). Coverage continues for type 2 diabetes, obstructive sleep apnea with obesity, cardiovascular risk reduction and MASH, and children and young adults under 21 can still be approved through EPSDT medical-necessity review.

Does Michigan Medicaid cover Wegovy or Zepbound?

Only narrowly. Since January 1, 2026, Michigan Medicaid covers Saxenda, Wegovy and Zepbound for weight management only at a BMI of 40 or higher, with documented failure of phentermine and Qsymia and a prescriber attestation that the drug is needed to avert bariatric surgery, in 6-month authorizations (MDHHS bulletin L 25-73, reported by Priority Health, December 15, 2025). Diabetes indications are unaffected.

What is the BALANCE model and does it lower my copay?

BALANCE is a voluntary federal model that lets state Medicaid programs buy GLP-1s (Wegovy, Zepbound KwikPen, Foundayo, Mounjaro, Ozempic, Rybelsus) at a negotiated net price of about $245 per 30-day supply, running May 2026 through December 2031 (KFF, May 11, 2026; Milliman). It does not set your copay; it makes coverage affordable enough that a state may add or keep it. Ask your state agency whether it applied by the July 31, 2026 deadline.

Does Medicaid cover Foundayo for weight loss?

It depends on the state, exactly as with Wegovy and Zepbound. Foundayo (orforglipron), approved April 1, 2026, is a weight-management drug, so states that exclude the obesity indication exclude it too, and it is one of the products in the federal BALANCE model (KFF, May 11, 2026). Medicaid enrollees cannot use Lilly's savings card, but LillyDirect self-pay is $149 to $299 a month by dose as of September 5, 2026.

Related guides

• Does Medicaid Cover Weight Loss Shots in 2026? State-by-State Coverage Rules
• Can I Get Weight Loss Shots on Medicaid in 2026? State-by-State Coverage Rules
• Will Medicaid Pay for Weight Loss Shots in 2026? State-by-State Coverage Rules
• Does Medicaid Cover Ozempic for Weight Loss in 2026? State-by-State Rules and What to Do When Denied
• Does Medicaid Cover Weight Loss Drugs in 2026? The State-by-State Answer
• Does Medicaid Cover Wegovy for Weight Loss? The State-by-State Answer for 2026

Sources

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
3. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205.
4. Williams E. Medicaid Coverage of and Spending on GLP-1s. KFF, January 16, 2026. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
5. KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid, May 11, 2026. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
6. KFF Health News. South Carolina Medicaid GLP-1 coverage and the withdrawn federal proposed rule, May 21, 2025. https://kffhealthnews.org/news/article/glp1-drugs-weight-loss-obesity-trump-medicaid-coverage-south-carolina/
7. Social Security Act, Section 1927(d)(2). Medicaid Drug Rebate Program statutory framework.
8. U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea. FDA News Release, December 2024.
9. U.S. Department of Health and Human Services Office of Inspector General. Special Advisory Bulletin: Pharmaceutical Manufacturer Copayment Coupons. HHS OIG, 2014.
10. Milliman. The evolving landscape of obesity coverage in Medicaid, March 19, 2026. https://www.milliman.com/en/insight/evolving-landscape-obesity-coverage-medicaid
11. Medi-Cal Rx. GLP-1 coverage changes effective January 1, 2026 (member notice). https://medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/member/GLP1_Changes.pdf
12. Pennsylvania Health Law Project. Pa. Medicaid ends adult coverage of GLP-1s for weight loss, December 22, 2025. https://www.phlp.org/en/news/pa-medicaid-ends-adult-coverage-of-glp-1s-for-weight-loss
13. New Hampshire DHHS. GLP-1 coverage change notification, October 9, 2025. https://nh.primetherapeutics.com/documents/51139/51630/Notification%2010.09.2025%20-%20GLP-1%20Coverage%20Change/218c7285-7968-9484-a244-859e0741eeba
14. NC Medicaid. NC Medicaid to reinstitute coverage of GLP-1s for weight management, December 19, 2025. https://medicaid.ncdhhs.gov/blog/2025/12/19/nc-medicaid-reinstitute-coverage-glp-1s-weight-management
15. Priority Health. Medicaid GLP-1 coverage changes effective January 1, 2026 (MDHHS bulletin L 25-73), December 15, 2025. https://www.priorityhealth.com/provider/manual/news/pharmacy/12-15-2025-medicaid-glp1-coverage-changes-effective-jan-1-2026
16. TennCare. Preferred Drug List effective September 1, 2026 (OptumRx). https://contenthub-aem.optumrx.com/content/dam/contenthub/onboarding/assets/Tenncare/Tenncare-PDL.pdf
17. New Mexico Health Care Authority. Weight reduction medications, seen September 5, 2026. https://www.hca.nm.gov/weight-reduction-medications/
18. healthinsurance.org. Does health insurance cover drugs used for weight loss? (Medicare GLP-1 Bridge), 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
19. GoodRx. Does Medicaid cover Ozempic, Wegovy and other GLP-1 medications? seen September 5, 2026. https://www.goodrx.com/insurance/medicaid/weight-loss-drug-coverage
20. Novo Nordisk. What to pay for Wegovy, seen September 5, 2026. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
21. Eli Lilly. LillyDirect Zepbound self-pay pricing (CMAT-05333 08/2026). https://www.lilly.com/lillydirect/zepbound
22. Eli Lilly. LillyDirect Foundayo self-pay pricing (CMAT-19155 08/2026). https://www.lilly.com/lillydirect/foundayo
23. FormBlends. Compounded GLP-1 Price Index, as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.